Literature DB >> 18721704

Third- and fourth-generation fluoroquinolones: retrospective comparison of endophthalmitis after cataract surgery performed over 10 years.

Michael K Jensen1, Richard G Fiscella, Majid Moshirfar, Barbara Mooney.   

Abstract

PURPOSE: To determine differences in endophthalmitis rates with prophylactic use of third- versus fourth-generation fluoroquinolones in cataract surgery.
SETTING: University hospitals.
METHODS: This retrospective cross-sectional (prevalence) study looked at patients who had phacoemulsification at a university eye center over a 10-year period. A nosocomial infectious reporting database was used to report endophthalmitis occurrences. The following were performed: a retrospective analysis of prospectively collected data to establish endophthalmitis rates, a prevalence analysis of the postoperative quinolone antibiotic prescribed, and a comparative analysis of endophthalmitis rate versus postoperative quinolone prescribed for all reported endophthalmitis cases. The main outcome measure was occurrence of endophthalmitis after cataract surgery.
RESULTS: From January 1997 to December 2007, 29276 patients had phacoemulsification cataract surgery. Forty cases of postoperative bacterial endophthalmitis were reported. The endophthalmitis rate from January 1997 to August 2003 associated with use of third-generation fluoroquinolones (ciprofloxacin, ofloxacin) was 0.197% (33/16710). The rate from September 2003 to December 2007 associated with fourth-generation fluoroquinolones (gatifloxacin, moxifloxacin) was 0.056% (7/12566). The difference between third- and fourth-generation drugs was statistically significant (P = .0011). Of fourth-generation fluoroquinolone infections, 0.015% (1/6651) and 0.1% (6/5915) were associated with gatifloxacin and moxifloxacin, respectively. The difference between drugs was statistically significant (P = .040).
CONCLUSIONS: The differences in the pharmacokinetic and pharmacodynamic properties of quinolone antibiotics may affect the endophthalmitis incidence after cataract surgery. The significant difference in endophthalmitis rates between gatifloxacin and moxifloxacin requires further study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18721704     DOI: 10.1016/j.jcrs.2008.05.045

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  25 in total

1.  Comparison of the influence of intracameral gentamicin, gatifloxacin, and moxifloxacin on the corneal endothelium in a rabbit model.

Authors:  Shinichiro Kobayakawa; Yoshimune Hiratsuka; Yasuo Watabe; Akira Murakami; Tetsuo Tochikubo
Journal:  Jpn J Ophthalmol       Date:  2010-11-05       Impact factor: 2.447

Review 2.  Modeling intraocular bacterial infections.

Authors:  Roger A Astley; Phillip S Coburn; Salai Madhumathi Parkunan; Michelle C Callegan
Journal:  Prog Retin Eye Res       Date:  2016-05-03       Impact factor: 21.198

Review 3.  Prophylaxis of postoperative endophthalmitis following cataract surgery: current status and future directions.

Authors:  Robert E Fintelmann; Ayman Naseri
Journal:  Drugs       Date:  2010-07-30       Impact factor: 9.546

4.  Prophylactic intracameral cefazolin and postoperative topical moxifloxacin after cataract surgery: endophthalmitis risk reduction and safety results in a 16-year study.

Authors:  Carlos L Moser; Monica Lecumberri Lopez; Magela Garat; Montserrat Martín-Baranera
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-08-07       Impact factor: 3.117

5.  Incidence of endophthalmitis after phacoemulsification cataract surgery: a Meta-analysis.

Authors:  Si-Lu Shi; Xiao-Ning Yu; Yi-Lei Cui; Si-Fan Zheng; Xing-Chao Shentu
Journal:  Int J Ophthalmol       Date:  2022-02-18       Impact factor: 1.779

6.  The comparison of clinical outcomes of endophthalmitis from fluoroquinolone-resistant and susceptible bacteria.

Authors:  Anita R Shirodkar; Harry W Flynn; Kyle Alliman; Geeta A Lalwani; Chrisfouad Alabiad; Andrew A Moshfeghi; Darlene Miller
Journal:  Clin Ophthalmol       Date:  2010-04-26

7.  Transporter targeted gatifloxacin prodrugs: synthesis, permeability, and topical ocular delivery.

Authors:  Sunil K Vooturi; Rajendra S Kadam; Uday B Kompella
Journal:  Mol Pharm       Date:  2012-10-11       Impact factor: 4.939

8.  Methicillin resistance of Staphylococcus species among health care and nonhealth care workers undergoing cataract surgery.

Authors:  Randall Olson; Eric Donnenfeld; Frank A Bucci; Francis W Price; Michael Raizman; Kerry Solomon; Uday Devgan; William Trattler; Steven Dell; R Bruce Wallace; Michelle Callegan; Heather Brown; Peter J McDonnell; Taryn Conway; Rhett M Schiffman; David A Hollander
Journal:  Clin Ophthalmol       Date:  2010-12-10

9.  Efficacy and tolerability of a combined moxifloxacin/dexamethasone formulation for topical prophylaxis in phacoemulsification: an open-label single-arm clinical trial.

Authors:  Cesar Ramon G Espiritu; Mary Ellen A Sy; Tommee Lynne G Tayengco
Journal:  J Ophthalmol       Date:  2011-05-25       Impact factor: 1.909

10.  Topical azithromycin or ofloxacin for endophthalmitis prophylaxis after intravitreal injection.

Authors:  Pedro Romero-Aroca; Laura Sararols; Lluis Arias; Ricardo P Casaroli-Marano; Francisca Bassaganyas
Journal:  Clin Ophthalmol       Date:  2012-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.